These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 32723804)
1. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393 [TBL] [Abstract][Full Text] [Related]
3. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630 [TBL] [Abstract][Full Text] [Related]
9. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Hayashi T; Maruyama S; Nangaku M; Narita I; Hirakata H; Tanabe K; Morita S; Tsubakihara Y; Imai E; Akizawa T; Clin J Am Soc Nephrol; 2020 May; 15(5):608-615. PubMed ID: 32245781 [TBL] [Abstract][Full Text] [Related]
10. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187 [TBL] [Abstract][Full Text] [Related]
12. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857 [TBL] [Abstract][Full Text] [Related]
13. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555 [TBL] [Abstract][Full Text] [Related]
14. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478 [TBL] [Abstract][Full Text] [Related]
16. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116 [TBL] [Abstract][Full Text] [Related]
17. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512 [TBL] [Abstract][Full Text] [Related]
18. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD. Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481 [TBL] [Abstract][Full Text] [Related]
20. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]